TC
VYNE icon

Truvestments Capital’s VYNE Therapeutics VYNE Stock Holding History

Truvestments Capital’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$15 Hold
25
– – ﹤0.01% 1163
2025
Q4 		$15 Hold
25
– – ﹤0.01% 1023
2025
Q3 		$8 Hold
25
– – ﹤0.01% 1046
2025
Q2 		$41 Hold
25
– – ﹤0.01% 941
2025
Q1 		$40 Buy
+25
New +$62 ﹤0.01% 1011

Other funds holding VYNE

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
TC
T3 Companies New York $76.8M AUM
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Truvestments Capital's VYNE Position: Q1 2026 in Review

Truvestments Capital held its VYNE Therapeutics (VYNE) position steady in Q1 2026 at 25 shares worth $15. The position accounts for ﹤0.01% of the portfolio, ranked #1163.

Truvestments Capital first reported a position in VYNE in Q1 2025 and has held it in 5 quarters since. The position peaked at $41 in Q2 2025. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

  • Truvestments Capital held 25 shares of VYNE Therapeutics worth $15 as of Q1 2026.
  • Truvestments Capital left its VYNE Therapeutics share count unchanged in Q1 2026.
  • VYNE Therapeutics made up ﹤0.01% of Truvestments Capital's portfolio in Q1 2026, its #1163 holding.
  • Truvestments Capital first reported a position in VYNE Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • Truvestments Capital's VYNE Therapeutics position peaked at $41 in Q2 2025.
  • 45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on Truvestments Capital's 13F filing for Q1 2026, filed 13 May 2026.